CellSource Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Masayuki Yamakawa
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 36.2% |
| Management average tenure | no data |
| Board average tenure | 2.9yrs |
Recent management updates
Recent updates
Investors Appear Satisfied With CellSource Co., Ltd.'s (TSE:4880) Prospects
Dec 16
Risks Still Elevated At These Prices As CellSource Co., Ltd. (TSE:4880) Shares Dive 31%
Apr 08We Think That There Are More Issues For CellSource (TSE:4880) Than Just Sluggish Earnings
Dec 20Some CellSource Co., Ltd. (TSE:4880) Shareholders Look For Exit As Shares Take 25% Pounding
Dec 19A Look At The Fair Value Of CellSource Co., Ltd. (TSE:4880)
Aug 13Shaky Earnings May Not Tell The Whole Story For CellSource (TSE:4880)
Jun 20CEO
Masayuki Yamakawa (61 yo)
Mr. Masayuki Yamakawa is CEO of CellSource Co. Ltd. from November 1, 2025 and its Director since. January 2022 and serves as its President from 2025.Mr. Yamakawa was Executive Chairman & MD of CellSource...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Representative Director | 3.9yrs | no data | 36.2% ¥ 2.8b | |
| Independent Outside Director | 2.9yrs | no data | 0.0045% ¥ 355.4k | |
| Chairman | 3.9yrs | no data | no data | |
| Director | 8.3yrs | no data | 0.32% ¥ 24.8m | |
| Independent Outside Director | 2.9yrs | no data | no data | |
| Director | 1.9yrs | no data | 6.84% ¥ 535.6m | |
| Independent Outside Director | less than a year | no data | no data |
Experienced Board: 4880's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/29 08:22 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/10/31 |
| Annual Earnings | 2025/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CellSource Co., Ltd. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Masatoshi Nagata | Ichiyoshi Research Institute Inc. |
| Kyoichiro Shigemura | Nomura Securities Co. Ltd. |
| Kota Maeda | Nomura Securities Co. Ltd. |